Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (203)	1/14/1998 3:31:00 PM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

more good results from imnr**************************************** stockfind.newsalert.com type in imnr for ompany digest see news after speaking with Dr.Richard Trauger at the company regarding the use of remune in veterinary medicine, which unforunately can not be use due to host specific production (Human only), we talked about the FDA. and i summarize, the fda needs to see that the immune system is responsible and that remune will enable it to help hiv infected individuals. this is the very crux that will allow approval and has been confirmed again from the studies released last nov.21 and this is in the absence of antiviral drug therapy. which means immune may also be allowed to be used on its own. major (w) pattern forming from this 2nd shake out. again good support at 10 this next rise must have intraday close above previous test at 13.25. hanging in here for that 1st quarter partner announcement. ar.